Drug
Nenocorilant
Nenocorilant: highest development phase Phase 1/2, developed by Corcept Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Corcept Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Nenocorilant 200 mg NCT07276373 | Phase 1/2 | Neoplasms |
Latest
No recent events.
Follow Nenocorilant on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.